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Abstract: The maintenance of mydriasis and the control of postoperative pain and   inflammation 
are critical to the safety and success of cataract and intraocular lens replacement surgery. 
Appropriate mydriasis is usually achieved by topical and/or intracameral administration of 
anticholinergic agents, sympathomimetic agents, or both, with the most commonly used 
being cyclopentolate, tropicamide, and phenylephrine. Ocular inflammation is common after 
cataract surgery. Topical steroids and nonsteroidal anti-inflammatory drugs are widely used 
because they have been proved effective to control postsurgical inflammation and decrease 
pain. Topical nonsteroidal anti-inflammatory drugs have also been shown to help maintain 
dilation. However, use of multiple preoperative drops for pupil dilation, inflammation, and 
pain control have been shown to be time consuming, resulting in delays to the operating room, 
and they cause dissatisfaction among perioperative personnel; their use can also be associated 
with systemic side effects. Therefore, ophthalmologists have been in search of new options to 
streamline this process. This article will review the current medications commonly used for 
intraoperative mydriasis, as well as pain and inflammation control. In addition, a new com-
bination of ketorolac, an anti-inflammatory agent, and phenylephrine, a mydriatic agent has 
recently been designed to maintain intraoperative mydriasis and to reduce postoperative pain 
and irritation from intraocular lens replacement surgery. Two Phase III clinical trials evaluating   
this combination have demonstrated statistically significant differences when compared to 
placebo in maintaining intraoperative mydriasis (P0.00001) and in reducing pain in the early 
postoperative period (P=0.0002). This medication may be of benefit for use in cataract and lens 
replacement surgery in the near future.
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Introduction
Appropriate mydriasis and inflammatory control during intraocular lens (IOL) exchange 
surgery is key to a successful surgical outcome.1,2 To achieve these aims, a myriad of 
topical and/or intracameral agents have been used to dilate the pupil and to control 
postoperative pain and inflammation. Therefore, ophthalmologists have been in search 
of new options to streamline the process of intraoperative mydriasis and to treat post-
operative inflammation. These new therapies include a combination of ketorolac, an 
anti-inflammatory agent, and phenylephrine, a mydriatic agent. Ketorolac acts as a 
nonselective cyclooxygenase (COX)-1/COX-2 inhibitor,3,4 and phenylephrine as an 
alpha-1 adrenergic receptor agonist.5,6 These compounds have shown effectiveness in 
controlling postoperative pain and inflammation and in the maintenance of mydriasis 
during surgery, respectively.6–10 Ketorolac has also shown beneficial effects in the 
maintenance of intraoperative mydriasis; however, there is no consensus on its use as a 
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  primary mydriatic agent in ophthalmic surgery.11 OMS302 is 
a new product developed by Omeros Corporation (Seattle, 
WA, USA), proprietary PharmacoSurgeryTM, that is targeted 
for use during IOL replacement (ILR) surgery, which includes 
cataract surgery and refractive lens exchange.12 (None of 
the authors have or have had any current or past financial   
interest, support or research participation in Omeros   
Corporation). The OMS302 combination is designed to 
maintain intraoperative mydriasis and reduce postoperative 
pain and inflammation resulting from ILR surgery.
ILR surgery involves replacement of the original lens 
of the eye with an artificial IOL. This procedure is typi-
cally performed to treat cataracts or to correct a refractive 
error (ie, refractive lens exchange).13–15 Maintenance of 
mydriasis is critical to the safety and surgical ease of the 
procedure.16 Intraoperative pupil constriction is associated 
with an increased risk of intraoperative complications, 
especially in difficult cases, and it can result in prolonged 
surgical time.17,18 In addition, the prevention of postoperative 
pain can improve patient satisfaction with the surgery and 
the surgeon.19 OMS302 may be added to a standard irriga-
tion solution used in ILR surgery and it can be delivered 
intracamerally to maintain mydriasis, to prevent miosis, and 
to reduce postoperative pain and inflammation.3
We will discuss the current status of ILR surgery includ-
ing the available methods for intraoperative maintenance of 
mydriasis and the control of postoperative pain and inflam-
mation. Then, we will review the progress and available data 
from the clinical research trials evaluating OMS302.
IOL replacement surgery
epidemiology
Approximately 30% of the population over 65 years of 
age in the UK has visually significant cataracts.20,21 An 
  estimated 17.2% of the United States population, or approxi-
mately 20.5   million people over the age of 40 years, will have   
a cataract in either eye.20,22 By 2020, this number in the US is 
expected to rise even further to 30.1 million.22   Currently,   cataracts   
are responsible for approximately 60% of Medicare costs   
associated with vision care.20 There are an estimated 3.6   million 
ILR procedures expected in the US this year, and 15 million 
in developed countries, with a projected annual growth rate 
of 3%–4%.3 Most commonly, the indication for ILR surgery 
is cataract extraction, although refractive lens exchange 
is a growing segment of the lens replacement market.13–15   
The most frequent indications for removing and replacing a 
current IOL are IOL dislocation/decentration, incorrect IOL 
power, glare/optical aberrations, and IOL calcification.23–27
Difficulties/complications of IOL 
replacement surgery
Mydriasis in cataract surgery
Appropriate mydriasis during IOL exchange surgery is key 
to a successful surgical outcome.1 Impaired visualization 
through a small pupil increases the chance of tissue damage, 
retained nuclear material, and vitreous loss.17,18 Currently, 
dilation is achieved by topical and/or intracameral adminis-
tration of anticholinergic agents, sympathomimetic agents, 
or both, with the most commonly used being cyclopentolate, 
tropicamide, and phenylephrine.28–31 Topical mydriatic agents 
have been used for many years to dilate the pupil before 
cataract surgery. However, the use of multiple preoperative 
drops for pupil dilation was shown to be inexact, and this 
could delay surgery, and cause dissatisfaction among peri-
operative personnel; moreover, their use is also associated 
with systemic side effects.28,29 Adverse ocular and systemic 
side effects make their use in high-risk patients (for example, 
hypertensive or elderly patients and children) more of a 
concern.30,31 Therefore, ophthalmologists have been in search 
of new options to streamline the process of intraoperative 
mydriasis. Available mydriatic agents and their side effects 
are summarized in Table 1.
Postoperative pain and inflammation
Ocular inflammation is common after cataract surgery. 
Untreated inflammation may cause pain, photophobia, and 
Table 1 Mydriatic agents for lens replacement surgery
Medication Mechanism of dilation Formulations Side effects
Phenylephrine Acts on the iris dilator muscle 2.5%, 5%, 10% Hypertension, syncope, myocardial infarction, 
tachycardia, and arrhythmia
Tropicamide Relaxation of the pupillary sphincter 0.5%, 1.0% Dry mouth, tachycardia, headache, and allergic 
reactions
Cyclopentolate Blocks contraction of the pupillary 
sphincter muscle
0.5%, 1.0%, 2.0% Disorientation, dry mouth, incoherent speech, 
or visual disturbances
Atropine Blocks contraction of the pupillary 
sphincter muscle
0.5%, 1.0%  Dry mouth, confusion, ventricular fibrillation, 
tachycardia, and nauseaClinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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other complications such as increased intraocular pressure, 
posterior capsule opacification, and cystoid macular edema.32 
Topical steroid therapy has been used for many years to con-
trol perioperative and postoperative inflammation, but it may 
inhibit corneal wound healing, increase intraocular pressure, 
increase the likelihood of infection, and lead to other serious 
complications.7,33–35 Topical nonsteroidal anti-inflammatory 
drugs (NSAIDs) are widely used because they have been 
proven effective in the control of postsurgical inflammation 
without the risks of steroid-related side effects.7,34,36,37 Pre-
operative treatment with NSAIDs, followed by combined 
therapy with NSAIDs and steroids postoperatively, has 
become the standard of care.36,38
Use of analgesic/mydriatic agents in IOL 
replacement surgery
Topical
Pharmacologic mydriasis can be achieved using a number 
of different topical agents. Phenylephrine is an adrenergic 
stimulant that acts on the iris dilator muscle. Its mydriatic 
effects have been known for some time.9,39,40 There are differ-
ent concentrations of phenylephrine and some studies have 
shown an increase in the effectiveness of dilation at higher 
concentrations.10,42 However, higher concentrations have also 
been associated with more systemic side effects.30,41–43 Side 
effects are mostly cardiovascular reactions, primarily seen 
in the high-risk populations such as among the elderly, 
hypertensive patients, and children, and these effects include 
a marked increase in blood pressure, myocardial infarction, 
arrhythmia, syncope, and tachycardia.44
Acetylcholine antagonists, such as tropicamide, allow 
for relaxation of the iris sphincter.45 A common regimen 
for cataract surgery, as mentioned previously, includes 
phenylephrine and tropicamide with or without cyclo-
pentolate. Topical tropicamide has been shown to cause 
nonocular reactions including dry mouth, allergic reac-
tions, headache, and tachycardia.44,46 Other muscarinic 
antagonists include cyclopentolate and atropine. Atropine 
is not as regularly used due to its long-lasting effects and 
given that evidence shows that there is not an increase in 
the mydriatic effect with the addition of atropine to the 
standard regimens.47
A new topical ocular insert, Mydriasert® (Spectrum 
Thea Pharmaceuticals Limited, Cheshire, UK) has also been 
evaluated for its efficacy and safety in its use for cataract 
surgery.48 It is a small, oblong, cylinder-shaped insert that 
includes 0.28 mg of tropicamide and 5.4 mg of phenylephrine 
hydrochloride. It is placed in the inferior fornix of the eye 
undergoing surgery. There was no statistically significant   
difference in the pupil diameter during surgery in patients using 
Mydriasert® versus those who received conventional topical 
dilating eye drops (tropicamide 1%, phenylephrine 10%, 
and cyclopentolate 1%).48 However, pupil size was restored 
to normal much more quickly (when evaluated at 24 hours) 
with Mydriasert® compared to conventional therapy. This 
effect is likely related to the lack of cyclopentolate in the 
insert, which is known for its long-lasting pupillary effects.48 
Importantly, this insert needs to be in place 60 minutes   
prior to surgery; however, it does provide the advantage of 
not having to instill multiple rounds of eye drops.48
The preoperative use of NSAIDs has also been shown 
to be effective in maintaining mydriasis during cataract 
surgery.1 Miosis during cataract surgery is thought to be 
partly related to an increase in the concentration of prosta-
glandins.49 NSAIDs work by their ability to inhibit COX, 
which ultimately decreases the production of prostaglan-
dins.50 In addition, steroids are known to block the release of 
arachidonic acid, which is also a precursor for prostaglandin 
synthesis.51 Options include, but are not limited to, ketorolac, 
nepafenac, flurbifrofen, and prednisolone. There is evidence 
that preoperative NSAIDs and/or steroid drops are effective 
in maintaining intraoperative mydriasis as compared to no 
other additional preoperative eye drops.1,52,53
Additionally, both NSAIDs and steroids are included 
in many perioperative drop regimens. Often, patients are 
maintained on an NSAID and a steroid drop for 2–4 weeks 
after cataract surgery for postoperative inflammation and 
pain control.51 Nepafenac, a topical NSAID, is often used 
starting 1 day prior to cataract surgery and continued for the 
first 2 weeks in the postoperative period. It is an inhibitor of 
COX-1/COX-2 and has shown efficacy in controlling pain 
and inflammation associated with cataract surgery.54–56 Nor-
mally, the nepafenac 0.1% ophthalmic suspension is used 
three times daily; however, a new once-daily 0.3% formula-
tion has been shown to be noninferior to nepafenac 0.1% in 
controlling inflammation and pain.57 Other available NSAIDs 
are presented in Table 2.
intracameral mydriatics
Intracameral mydriatics were introduced in 2003, and 
the original compound included a preservative-free 
mixture of cyclopentolate 0.1%, phenylephrine 1.5%, 
and lidocaine 1%.29 Cyclopentolate later demonstrated 
no additional mydriatic effects to phenylephrine 1.5% 
when administered together with lidocaine.58 It has also 
been established that the addition of epinephrine to the Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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irrigating solution is not necessary when intracameral 
mydriatics are being used.59 Intracameral mydriatics have 
been shown to provide sufficient pupil dilation without 
causing measurable ocular side effects or influencing the 
phacoemulsification procedure negatively, as compared to 
topical mydriatics.29,60,61
One of the early randomized, controlled studies of intra-
cameral injections29 evaluated 60 patients who received either 
intracameral injection of mydriatics in phacoemulsifica-
tion cataract surgery versus conventional topical therapy.   
One group received topical mydriatics comprised of three 
drops of cyclopentolate 1% and phenylephrine 1%, which 
were given 15 minutes apart, and 150 μL of intracameral 
lidocaine hydrochloride 1%. The other group received intra-
cameral mydriatics including 150 μL of cyclopentolate 0.1%, 
phenylephrine 1.5%, and lidocaine hydrochloride 1% with 
placebo eye drops. The patients with intracameral mydriatics 
achieved rapid results with 95%±3% (standard deviation) of 
the final value of mydriasis within 20 seconds. Intracameral 
mydriatics were effective and safe as well. However, the 
pupils tended to be slightly smaller than in the topical group 
(mean 6.7±1.0 mm versus 7.7±1.0 mm; P0.001), but the 
pupils did not contract intraoperatively.
Over time, other intracameral combinations were studied, 
and it was found that similar levels of effectiveness could be 
achieved with fewer medications in the formulation.29,60,61 
A study evaluated intraoperative mydriasis in 31 consecutive 
eyes scheduled for phacoemulsification cataract extraction 
and IOL implantation using an intracameral injection of   
0.2–0.3 mL of preservative-free 1% lidocaine without any addi-
tional preoperative or intraoperative mydriatics.62 The mean 
pupil diameter after intracameral lidocaine was signifi-
cantly greater than the baseline pupil size, and it increased 
by 4.39±0.53 mm. The pupil dilation was found to be satisfac-
tory, persistent, and stable throughout the duration of the cata-
ract surgery.62 Previously, Cionni et al63 used lidocaine 1% 
as a single intracameral mydriatic agent with the addition of 
epinephrine to the irrigation fluid, and it showed adequate 
dilation for cataract surgery in 12 patients.
Intracameral lidocaine has also been shown to relieve 
intraoperative discomfort related to iris movement or 
manipulation.64,65 The amount of 0.1–0.5 mL of unpre-
served lidocaine can be injected into the anterior chamber 
for intraoperative pain control. Combined topical and 
intracameral anesthesia is well tolerated and it is effective 
in maintaining a low pain score during cataract surgery in 
most patients (approximately 76% of patients).66 Intracameral   
triamcinolone acetonide has also shown effectiveness in 
the prevention of postoperative anterior chamber inflam-
mation in patients undergoing phacoemulsification67 and 
phacotrabeculectomy.67,68
The intracameral method has also been suggested to 
improve the operating conditions in more complicated cata-
ract surgeries, including those with intraoperative floppy iris 
syndrome, by stabilizing the iris during surgery.69–72 A recent 
study72 evaluated the efficacy of intracameral phenylephrine 
on 42 patients receiving tamsulosin and undergoing cataract 
surgery. Intracameral phenylephrine was found to be highly 
effective for prophylaxis of floppy iris syndrome by reversing 
intraoperative floppy iris, restoring iris rigidity and causing 
the pupil to return to its normal preoperative size.72
Mechanical
If the necessary pupil dilation cannot be achieved with 
medications alone, then alternative mechanical devices 
are available for dilation assistance. The next step in pupil 
dilation involves mechanical stretching of the pupil.73 Other 
options include iris retainers, which are devices developed 
to hold the iris in an enlarged state, or physical cutting of 
the iris sphincter.73 Adjunct devices for pupil expansion 
include nylon iris hooks, the Beehler pupil dilator (MORIA 
SA, Antony, France), and pupillary rings, including the 
Perfect Pupil (Milvella Limited, North Sydney, NSW, 
Australia), the Graether 2000 pupil-expander system   
Table 2 Available nonsteroidal anti-inflammatory drugs
Drug Formulations Preparation FDA approved
indomethacin 1% indole Available outside of the US
Flurbiprofen 0.03% water-soluble phenylalkanoic acid Approved for intraoperative use during cataract surgery 
for the inhibition of miosis
Suprofen 1% water-soluble phenylalkanoic acid Approved for intraoperative use during cataract surgery 
for the inhibition of miosis
Ketorolac tromethamine 0.5% water-soluble phenylalkanoic acid Postoperative inflammation and pain control
Diclofenac 1% water-soluble phenylalkanoic acid Minimize inflammation related to cataract surgery
Bromfenac 0.09% water-soluble phenylalkanoic acid Postoperative inflammation
Nepafenac 0.1% Prodrug arylacetic acid Pain and inflammation associated with cataract surgery
Abbreviation: FDA, Food and Drug Administration.Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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(Eagle Vision, Inc., Memphis, TN, USA), the Malyugin 
Ring® (MicroSurgical Technology, Redmond, WA, 
USA), and the Morcher pupil dilator (Morcher, Stuttgart,   
Germany).17,74–77
Efficacy of phenylephrine and ketorolac 
on intraoperative mydriasis and 
postoperative pain control
Phenylephrine is a selective alpha-1 adrenergic receptor 
agonist, which has mydriatic effects on the iris.9,39,40 It has 
shown success both topically and intracamerally in main-
taining mydriasis during cataract surgery.9,10,29,70 Several 
concentrations of phenylephrine have been evaluated and 
several studies have shown an increase in effectiveness 
of pupil dilation with higher concentrations.10,40 However, 
other studies differ in their conclusions. One study found 
that 2.5% phenylephrine is as effective as 10% phenylephrine 
in the maintenance of mydriasis during both extracapsular 
and phacoemulsification cataract extraction when used in 
conjunction with cyclopentolate.78 Importantly, with the use 
of a lower concentration of phenylephrine, there is a lower 
risk of systemic side effects.
Phenylephrine has been combined with a number of other 
topical drops to evaluate improvements in dilation and main-
tenance of dilation during cataract surgery. Most commonly, 
phenylephrine is combined with tropicamide. The use of 
tropicamide 1.0% and phenylephrine 2.5% proved to be an 
effective preoperative regimen for mydriasis in phacoemulsi-
fication, and it showed improved dilation compared to lower 
concentrations of tropicamide 0.5% and phenylephrine 0.5% 
with equal safety profiles.8
Ketorolac has been approved in the US for treatment of 
postoperative pain and inflammation after cataract surgery. 
Ketorolac has been used successfully in the alleviation of 
ocular inflammation and pain, the prevention and treatment 
of postoperative cystoid macular edema, and the prevention 
of intraoperative miosis.7,79–80 Use of twice-daily ketoro-
lac 0.45% for 16 days beginning 1 day before surgery resulted 
in a greater percentage of patients with an ocular inflamma-
tory score of 0 on day 14 (52.5% compared to 26.5% in the 
vehicle group) and a greater number of patients with a pain 
score of 0 on day 1 postoperatively (72.4% versus 39.7%, 
respectively).79 Topically, it is available in 0.4%, 0.5%, 
and 0.45% concentrations (ACULAR LS®, ACULAR®, and 
ACUVAIL®; Allergan, Inc., Irvine, CA, USA). It was first used 
at a concentration of 0.5% for the treatment of conjunctivitis 
and pain; however, lower concentrations have since become 
available, and the preservatives have also been changed to 
assist in patient comfort upon instillation. Ketorolac 0.45% 
was found to be superior in its ability to inhibit prostaglandin 
E2 compared to nepafenac 0.1% and bromfenac 0.09%, which 
are used in patients undergoing phacoemulsification. Prosta-
glandin E2 is a mediator of inflammatory signals within the 
COX pathway and it can also enhance the constrictor action of 
the iris sphincter through mechanisms that are not dependent 
on cholinergic receptors.81–83 Ketorolac tromethamine 0.5% 
was also better than prednisolone acetate 1% solutions in 
preventing surgically-induced miosis.11
Given the success of these two medications with cataract 
surgery, the thought of combining the two for use in intraop-
erative administration was implemented. The two medica-
tions would work synergistically in the establishment and 
maintenance of pupillary dilation and would prevent/control 
postoperative pain and inflammation to improve patient 
comfort and satisfaction.
Early research on ketorolac/ 
phenylephrine or OMS302
A number of the early clinical trials have reported success in   
the use of OMS302 in the maintenance of pupillary dilation 
during cataract surgery and in the prevention of postoperative 
pain and inflammation.84–87 In a Phase IIB study, 223 subjects 
undergoing cataract extraction with lens replacement were 
randomized to receive treatment with one of the following: 
balanced salt solution only (vehicle); phenylephrine; ketoro-
lac; or OMS302.84
Results from this study were announced in 2011 by 
Omeros Corporation. They reported that OMS302 and 
phenylephrine demonstrated significant improvement in the 
maintenance of intraoperative mydriasis, compared with vehi-
cle and ketorolac alone (P0.00001 for both comparisons).84   
They found that pupil diameter steadily decreased through-
out the surgical procedure in both the vehicle and ketorolac 
groups, and vehicle and ketorolac use resulted in pupillary 
constriction greater than 4 mm from baseline. More than 20% 
of subjects in the vehicle-controlled group experienced a 
decrease in pupillary diameter of 2.5 mm or more during 
surgery. In contrast, only 4.4% of OMS302-treated subjects 
experienced this level of pupillary constriction.84
In addition, they found patients treated with OMS302 or 
ketorolac alone had significantly less pain in the early post-
operative period than patients who received vehicle or phe-
nylephrine alone (P0.05 for both comparisons). Moderate to   
severe pain was reported by 17% of vehicle-treated subjects. 
They reported that OMS302 was safe and well-tolerated by 
the patient population.84Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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In the first Phase III trial, including over 400   participants, 
Omeros reported that OMS302 demonstrated statistically 
significant superiority over placebo in the maintenance of 
intraoperative mydriasis and a reduction of postoperative 
pain (both P0.00001).87
Safety data were collected until postoperative day 90. The 
results from the first Phase III clinical trial were presented 
at the American Academy of Ophthalmology Meeting in 
Chicago, November 2012.89,90 It was a 405-subject random-
ized, double-blind, and placebo-controlled study in which 
all patients received preoperative mydriatics and anesthetics.   
The investigators found that OMS302 was delivered 
intracamerally in balanced salt solution during the IOL 
replacement surgery. OMS302 was superior to placebo in 
maintaining mydriasis (P0.0001) and preventing pain 
(P0.0001). Fewer OMS302-treated subjects experienced 
a pupil diameter 6 mm at cortical clean up (P0.0001) 
or moderate-to-severe pain (P=0.006), and more patients 
were pain-free (P=0.011). Adverse events were similar 
between the two groups. Therefore, their conclusion was 
that OMS302 significantly maintained mydriasis, prevented 
miosis, and decreased postoperative pain.90 Additionally, 
a second trial was designed and initiated to evaluate the 
same efficacy and safety measures as the earlier Phase IIB 
and Phase III clinical trials.85 In November 2012, Omeros 
Corporation announced that OMS302 met the coprimary 
efficacy end points in this second pivotal Phase III clinical 
trial by demonstrating statistically significant differences in 
the maintenance of intraoperative mydriasis (P0.00001) 
and in the reduction of pain in the early postoperative period 
(P=0.0002) between OMS302 and placebo.85,88 Pupil con-
striction of at least 3 mm was common in control patients, 
while constriction 1 mm was uncommon in OMS302-
treated patients. Safety data were collected until postopera-
tive day 90. OMS302 was reported to be well-tolerated in 
this Phase III clinical trial.85 The incidence of adverse events 
was similar between the two treatment groups. Additionally, 
the adverse event profile was comparable to those seen in 
prior OMS302 clinical trials.84,87
In November of 2013, the combined results of the   
two Phase III clinical trials (both including 400 partici-
pants) were presented as a scientific poster at the   American 
Academy of Ophthalmology Annual Meeting in New 
Orleans.91 The results showed that OMS302 maintained a 
necessary pupil diameter throughout the IOL replacement 
procedure, while the placebo group showed progressive 
constriction (P0.00001). Fewer OMS302-treated patients 
(3%) compared to placebo-treated patients (27%) 
experienced 2.5 mm pupillary constriction, representing 
a 50% decrease in the operative field (P0.001) during the 
surgery.92 Larger randomized clinical trials are warranted to 
provide evidence of the safety profile and efficacy of this for-
mulation, OMS302, of its goal of maintaining mydriasis and 
preventing pain associated with IOL replacement surgery.
Current ongoing research  
on the medication
Approvals in europe and the US  
for use in ophthalmic surgery
The US Food and Drug Administration (FDA) has accepted 
a proposed brand name for OMS302, OmidriaTM (Omeros 
Corporation). The acceptance of the proprietary brand name 
by the FDA is subject to the agency’s final determination 
prior to any approval of the product’s new drug application 
and market launch, expected in 2014. Omeros Corporation 
previously provided the trademark application for Omid-
riaTM from the United States Patent and Trademark Office 
(  Alexandria, VA, USA). The company also submitted 
the brand name, OmidriaTM, to the European Medicines 
Agency, with a decision anticipated soon. Omeros Cor-
poration also recently registered OmidriaTM as a European 
Community Trade Mark. Finally, Omeros Corporation has 
also received permission by the FDA to study OMS302 in 
the pediatric population undergoing primary cataract 
extraction, and the results will likely be available in the 
postmarketing period.93
Clinical trials ongoing or completed
There are four clinical trials84–87 listed in Clinicaltrials.gov 
(see Table 3). Omeros Corporation has recently presented the 
most currently available results at the American Academy 
of Ophthalmology Annual Meeting in 2013;91 however, the 
final official results and the report’s submission to a peer-
reviewed journal are still pending.
Conclusion
Appropriate mydriasis and inflammatory control during 
intraocular lens exchange surgery is key to a successful 
surgical outcome.1,2 To achieve these, a myriad of topical 
and/or intracameral agents have been used to dilate the pupil 
and to control postoperative pain and inflammation, as we 
have reviewed. A prospective new therapy, OMS302, is a 
combination of ketorolac, an anti-inflammatory agent, and 
phenylephrine, a mydriatic agent. At this time, the available 
evidence in peer-reviewed literature for this new agent is 
limited. We believe larger studies testing the efficacy and Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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safety profile of this new formulation are warranted to pro-
vide more evidence that supports its use.
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